HIV Drug Resistance Surveillance in Countries Scaling Up Pre-exposure Prophylaxis
November 25, 2020

HIV Drug Resistance Surveillance in Countries Scaling Up Pre-exposure Prophylaxis

This technical guidance describes the methods and implementation considerations to monitor the prevalence of HIV drug resistance among PrEP users diagnosed with HIV through a cross-sectional survey. The outcomes of the survey will be used to inform the selection of maximally effective first-line combination antiretroviral therapy for PrEP users who acquire HIV.

This technical guidance describes the methods and implementation considerations to monitor the prevalence of HIV drug resistance among PrEP users diagnosed with HIV through a cross-sectional survey. The outcomes of the survey will be used to inform the selection of maximally effective first-line combination antiretroviral therapy for PrEP users who acquire HIV.

Organizations:

World Health Organization (WHO)

Share article: